In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

@article{Mason2008InVE,
  title={In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.},
  author={Kylie D. Mason and Cassandra J Vandenberg and Clare L Scott and Andrew H Wei and Suzanne Cory and David C S Huang and Andrew W Roberts},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 46},
  pages={
          17961-6
        }
}
Deregulated Myc expression drives many human cancers, including Burkitt's lymphoma and a highly aggressive subset of diffuse large cell lymphomas. Myc-driven tumors often display resistance to chemotherapeutics because of acquisition of mutations that impair the apoptosis pathway regulated by the Bcl-2 protein family. Given the need to identify new therapies for such lymphomas, we have evaluated the efficacy of ABT-737, a small molecule that mimics the action of the BH3-only proteins, natural… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 53 CITATIONS, ESTIMATED 51% COVERAGE

Exploiting mitochondrial apoptosis for the treatment of cancer.

  • Mitochondrion
  • 2010
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The BCL-2 arbiters of apoptosis and their growing role as cancer targets

  • Cell Death and Differentiation
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

The BCL-2 protein family: opposing activities that mediate cell death

  • Nature Reviews Molecular Cell Biology
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

The E -myc transgenic mouse: A model for high-incidence spontaneous lymphoma and leukemia of early B cells

AW Harris
  • J Exp Med
  • 1988
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL